Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Dendreon Jumps as More Doctors Prescribe Cancer Therapy

Dendreon Jumps as More Doctors Turn to Provenge
The Dendreon Corp. headquarters stands in Seattle, Washington. Photographer: Kevin P. Casey/Bloomberg

Dendreon Corp. rose the most in nine months after announcing a third-quarter loss that was less than analysts’ estimates and saying more doctors are using its prostate cancer drug Provenge.

The biotechnology company jumped 16 percent to $4.47 at the close in New York, its biggest single-day advance since Feb. 6. The Seattle-based drugmaker had a loss of 33 cents a share, excluding a restructuring charge. Analysts had expected a loss of 82 cents, according to the average of 22 estimates compiled by Bloomberg.

Urologists prescribing Provenge grew 14 percent in the quarter, Dendreon said today in a statement. The number of oncologists doing so fell by less than 1 percent, an improvement from an 8 percent slide in the second quarter. The medicine accounted for two-thirds of Dendreon’s sales last year and faces competition from new drugs from Johnson & Johnson and Medivation Inc.

“We delivered strong growth in urology and have continued to improve results in oncology,” Chief Executive Officer John H. Johnson said in a statement today.

The quarter’s net loss of $154.9 million, or $1.04 a share, compared with a net loss of $147.1 million, or $1, a year earlier, Dendreon said.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.